INSIGHTS ON PHARMACEUTICAL LOGISTICS

• Collaborative Supply Chain Management In A Fragmented World

  Biopharma supply chains are under pressure. As regionalization accelerates, success depends on agility, trust, and new approaches to collaboration that can withstand ongoing global uncertainty.

• Quality Roundtable: Raw Material Planning For Tech Transfer And Scaling Biologics

  Join this roundtable of biopharmaceutical professionals as they share their insights to help you navigate important quality and planning decisions for the progression of your biologic.

• Biopharma Supply, Reimagined: Blarney, A Climate-Neutral Facility For Best-In-Class Filters

  Explore how a new, climate-neutral manufacturing facility strengthens biopharma supply chains. Understand the benefits of its advanced filtration technologies and commitment to environmental sustainability.

• Moving Batch Release Into The Fast Lane

  Complex supply chains and fragmented systems slow batch release, delaying patient access and revenue goals. Learn how automation and centralized data improve compliance and accelerate delivery.

• Risk Mitigation For Late-Stage Clinical Assets

  6/11/2025

  Leveraging the competence and capabilities of the CDMO to bring forth innovative, flexible solutions to safeguard supply chains for their clients and, ultimately, for patients is crucial to strategic partnering.

• The Importance Of Quality In Raw Material Selection

  1/16/2025

  Learn how to select high-quality raw materials for cell-based manufacturing in this exploration of the criticality of raw materials, from preclinical development to commercialization. 

• Windsor Framework: What Is It?

  9/2/2025

  Learn about the Windsor Framework and how it addresses the challenges of medicine supply chains between the UK and the EU, creating stability and certainty in the post-Brexit world.

• How To Select The Right Fill-Finish CDMO For Phase I–II

  3/16/2026

  Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

• Strengthen Pharmaceutical Supply Chains With A U.S.-Based CDMO

  6/5/2025

  While certain ingredients require sourcing abroad, partnering with a U.S.-based company that owns its manufacturing assets allows for direct oversight of product quality and supply reliability.